Group 1 - Recordati's subsidiary in China, Ruikangdi, has officially exited the Chinese market, ceasing the supply of three rare disease drugs, which may disrupt treatment for patients [1][2] - The drug with the most significant impact from the exit is the innovative drug Shireza, which has no domestic generic alternatives, potentially leaving Cushing's syndrome patients without medication [1][2] - Approximately 40,000 to 50,000 patients in China suffer from Cushing's syndrome, with only about 3,000 requiring drug treatment [1] Group 2 - Ruikangdi, a small enterprise focused on rare diseases, is a subsidiary of Recordati, which operates in around 150 countries and has been involved in the rare disease sector since 1990 [2] - The direct reason for the market exit was a failure in health insurance negotiations, as two of its drugs did not make it into the 2025 health insurance directory [2] - The challenges faced by rare disease drug companies in China include high investment costs with low returns, as the development cost for a single orphan drug is approximately 260 million yuan, while the rare disease drug market in China accounts for only 3% of the global market [3] Group 3 - The Chinese rare disease patient population exceeds 20 million, with over 200,000 new patients added each year [3] - The industry is facing insufficient health insurance coverage, with 83% of rare disease drugs having annual treatment costs exceeding 300,000 yuan, and only 50% being included in health insurance [3] - Policy initiatives are being explored to address these challenges, such as the Boao Lecheng Pilot Zone allowing expedited approval for unapproved drugs and encouraging local innovation in the rare disease sector [3]

Core Viewpoint - The commercialization of Phosphate Oglazostatin Tablets (brand name: Shiruisa) marks a significant advancement in the treatment of Cushing's syndrome in China, filling a gap in the market for oral medications for this rare disease [1] Group 1: Product Launch and Approval - Phosphate Oglazostatin Tablets are the only approved oral medication for adult Cushing's syndrome in China, officially launched on April 12 [1] - The drug is a First-in-Class innovation from Recordati Group's subsidiary in China, and has received orphan drug designation in the US, EU, and Australia [1] - The drug was granted priority review and approval by the National Medical Products Administration (NMPA) in September 2023, with import approval expected in September 2024 [1] Group 2: Clinical Efficacy and Safety - Global clinical studies have demonstrated the efficacy and safety of Phosphate Oglazostatin Tablets, with a three-phase clinical trial involving 210 patients showing significant cortisol level reduction and sustained efficacy for over four years [1] - Chinese patients exhibit higher sensitivity to the drug, requiring approximately half the daily dosage compared to patients in Europe and the US [1] Group 3: Impact on Treatment Paradigm - The introduction of the new drug is expected to optimize surgical outcomes for Cushing's syndrome, allowing non-surgical patients the opportunity for surgery and improving the physical condition of surgical candidates [2] - The focus of treatment is shifting towards comprehensive recovery for patients, addressing not only cortisol levels but also the broader impacts of Cushing's syndrome, including cardiovascular risks and psychological health [2] - The recurrence rate post-surgery can be as high as 25% over ten years, prompting a shift towards a "one-time Cushing's, lifelong follow-up" treatment model, which the new drug will facilitate [2]